CYP2A6 Longitudinal Effects in Young Smokers

被引:6
|
作者
Cannon, Dale S. [1 ]
Medina, Tait R. [2 ,3 ]
Mermelstein, Robin J. [3 ,4 ]
Hedeker, Donald [5 ]
Bakian, Amanda V. [1 ]
Coon, Hilary [1 ]
Cook, Edwin H. [6 ]
Hamil, Cindy [7 ]
Weiss, Robert B. [7 ]
机构
[1] Univ Utah, Sch Med, Dept Psychiat, 650 Komas Dr,Suite 206, Salt Lake City, UT 84108 USA
[2] Indiana Univ, Dept Sociol, Bloomington, IN USA
[3] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA
[4] Univ Illinois, Dept Psychol, Chicago, IL 60680 USA
[5] Univ Chicago, Dept Hlth Sci, Chicago, IL 60637 USA
[6] Univ Illinois, Dept Psychiat, Inst Juvenile Res, Chicago, IL 60612 USA
[7] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA
基金
美国国家卫生研究院;
关键词
NICOTINE DEPENDENCE; SMOKING-BEHAVIOR; TOBACCO DEPENDENCE; ADOLESCENT SMOKERS; METABOLISM; ADDICTION; MOTIVES; MODEL; RISK;
D O I
10.1093/ntr/ntv049
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: The present study sought to identify time-dependent within-participant effects of CYP2A6 genotypes on smoking frequency and nicotine dependence in young smokers. Methods: Predicted nicotine metabolic rate based on CYP2A6 diplotypes (CYP2A6 diplotype predicted rate [CDPR]) was partitioned into Normal, Intermediate, and Slow categories using a metabolism metric. Growth-curve models characterized baseline and longitudinal CDPR effects with data from eight longitudinal assessments during a 6-year period (from approximately age 16-22) in young smokers of European descent (N = 296, 57% female) who had smoked less than 100 cigarettes lifetime at baseline and more than that amount by Year 6. Phenotypes were number of days smoked during the previous 30 days and a youth version of the Nicotine Dependence Syndrome Scale (NDSS). A zero-inflated Poisson growth-curve model was used to account for the preponderance of zero days smoked. Results: At baseline, Intermediate CDPR was a risk factor relative to both Normal and Slow CDPR for smoking frequency and the NDSS. Slow CDPR was associated with the highest probability of smoking discontinuation at baseline. However, due to CDPR time trend differences, by young adulthood these baseline effects had been reordered such that the greatest risks for smoking frequency and the NDSS were associated with Normal CDPR. Conclusions: Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in novice smokers. However, differences in the time-by-CDPR effects result in a reordering of genotype effects such that normal metabolism becomes the risk variant by young adulthood, as has been reliably reported in older smokers.
引用
收藏
页码:196 / 203
页数:8
相关论文
共 50 条
  • [31] Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations
    Twesigomwe, David
    Droegemoeller, Britt I.
    Wright, Galen E. B.
    Adebamowo, Clement
    Agongo, Godfred
    Boua, Palwende R.
    Matshaba, Mogomotsi
    Paximadis, Maria
    Ramsay, Michele
    Simo, Gustave
    Simuunza, Martin C.
    Tiemessen, Caroline T.
    Lombard, Zane
    Hazelhurst, Scott
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (03) : 576 - 594
  • [32] Smoking behavior and related cancers:: The role of CYP2A6 polymorphisms
    Nakajima, Miki
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2007, 9 (06) : 538 - 544
  • [33] In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity
    Tiong, K. H.
    Yiap, B. C.
    Tan, E. L.
    Ismail, R.
    Ong, C. E.
    XENOBIOTICA, 2010, 40 (07) : 458 - 466
  • [34] Differential Effects of Nicotine Treatment and Ethanol Self-Administration on CYP2A6, CYP2B6 and Nicotine Pharmacokinetics in African Green Monkeys
    Ferguson, C. S.
    Miksys, S.
    Palmour, R. M.
    Tyndale, R. F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 343 (03) : 628 - 637
  • [35] Nicotine metabolism:: the impact of CYP2A6 on estimates of additive genetic influence
    Swan, GE
    Benowitz, NL
    Lessov, CN
    Jacob, P
    Tyndale, RF
    Wilhelmsen, K
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (02) : 115 - 125
  • [36] CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China
    Huang, Feng-mao
    Chen, Han-chun
    Khan, Md. Asaduzzaman
    Yang, Fu-lan
    Wan, Xin-xing
    Xu, Ai-hua
    Ou-yang, Fang-dan
    Zhang, Dian-zheng
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [37] In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
    di Iulio, Julia
    Fayet, Aurelie
    Arab-Alameddine, Mona
    Rotger, Margalida
    Lubomirov, Rubin
    Cavassini, Matthias
    Furrer, Hansjakob
    Guenthard, Huldrych F.
    Colombo, Sara
    Csajka, Chantal
    Eap, Chin B.
    Decosterd, Laurent A.
    Telenti, Amalio
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) : 300 - 309
  • [38] Structure?activity relationship and in vitro inhibition of human cytochrome CYP2A6 and CYP2A13 by flavonoids
    Boonruang, Supattra
    Prakobsri, Khanistha
    Pouyfung, Phisit
    Prasopthum, Aruna
    Rongnoparut, Pornpimol
    Sarapusit, Songklod
    XENOBIOTICA, 2020, 50 (06) : 630 - 639
  • [39] Roles of human CYP2A6 and rat CYP2B1 in the oxidation of (+)-fenchol by liver microsomes
    Miyazawa, M.
    Gyoubu, K.
    XENOBIOTICA, 2007, 37 (09) : 943 - 953
  • [40] CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response
    Fang, Chao
    Ouyang, Wen
    Zeng, Youjie
    Pei, Qi
    Xia, Yuhao
    Luo, Siwan
    Chen, Minghua
    FRONTIERS IN PHARMACOLOGY, 2022, 13